痛风患者使用别嘌醇的死亡率:系统综述与荟萃分析
该系统综述与荟萃分析检索了截至2018年8月的文献,纳入4项队列研究,评估痛风患者使用别嘌醇与全因死亡率及心血管死亡率的关系。汇总分析显示别嘌醇使用与全因死亡率无显著关联(校正HR 0.80,95%CI 0.60-1.05),但纳入研究数量少,需进一步研究。
要点
- 痛风患者使用别嘌醇与全因死亡率无显著关联(校正HR 0.80,95%CI 0.60-1.05)。
- 纳入的4项研究中2项发现别嘌醇有保护作用,1项无显著关联,1项剂量递增无显著影响。
- 纳入研究数量少,证据有限,需更多研究验证长期效果。
核心结论
- 痛风患者使用别嘌醇与全因死亡率无显著关联(校正HR 0.80,95%CI 0.60-1.05)。
- 纳入研究数量少,需进一步研究确认长期效果。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、CINAHL和Cochrane Library从建库至2018年8月。
- 纳入标准为队列设计,评估痛风患者使用别嘌醇与心血管或全因死亡率的关系。
- 共纳入4篇报告全因死亡率风险估计的文章,其中2篇也报告心血管死亡率。
- 使用纽卡斯尔-渥太华量表评估文章质量,进行叙述性综合并在可能时汇总风险估计数据。
主要发现
- 4篇文章报告了痛风患者使用别嘌醇的全因死亡率风险估计(HR),其中2篇也报告心血管死亡率。
- 2篇文章发现别嘌醇对痛风患者有保护作用,1篇未发现统计学显著关联,1篇未发现别嘌醇剂量增加对全因或心血管死亡率有统计学显著影响。
- 全因死亡率数据可汇总,与未使用别嘌醇的痛风患者相比,使用别嘌醇者全因死亡率无显著关联(校正HR 0.80,95%CI 0.60-1.05)。
关键数值与推荐
- 全因死亡率汇总校正HR 0.80(95%CI 0.60-1.05),比较痛风患者使用别嘌醇与未使用别嘌醇。
临床怎么用
- 基于当前证据,痛风患者使用别嘌醇与全因死亡率无显著关联,临床决策应综合考虑其他因素。
局限性
- 纳入研究数量少,证据有限。
- 仅4篇文章报告全因死亡率风险估计,其中2篇报告心血管死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Urate-lowering therapy (predominantly allopurinol) is highly effective as a treatment for gout, but its wider long-term effects remain unclear. This systematic review and meta-analysis aimed to ascertain the association between mortality and the use of allopurinol in patients with gout. METHOD: Medline, Embase, CINAHL, and the Cochrane Library were searched from inception to August 2018. Articles eligible for inclusion used a cohort design and examined cardiovascular or all-cause mortality in patients diagnosed with gout and prescribed allopurinol. Information on study characteristics, design, sample size, and mortality risk estimates were extracted. Article quality was assessed using the Newcastle-Ottawa Scale. Included articles were described in a narrative synthesis and, where possible, risk estimate data were pooled. RESULTS: Four articles reported a hazard ratio (HR) risk estimate for all-cause mortality in patients with gout using allopurinol, and 2 of these also reported cardiovascular mortality. Two articles found allopurinol to be protective in patients with gout, 1 found no statistically significant association, and 1 found no statistically significant effect of escalation of allopurinol dosage on all-cause or cardiovascular-related mortality. Data pooling was possible for all-cause mortality and found no association between allopurinol use in patients with gout and all-cause mortality compared to patients with gout not using allopurinol (adjusted HR 0.80 [95% confidence interval 0.60-1.05]). CONCLUSION: There was no significant association between all-cause mortality and allopurinol use in people with gout. However, the number of included studies was small, suggesting that further studies are needed.
引用
- Hay CA, Prior JA, Belcher J, et al. Mortality in Patients With Gout Treated With Allopurinol: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2021. PMID: 32286732. doi:10.1002/acr.24205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。